Riskpilot← Back to searchSign inGet full accessSpecio AB
ABActiveOrg 5591087662Lägergränden 15Medical specialists activities · NACE 8622Est. 20171 employees
Revenue 2024
SEK 274K
+172% vs 2023
EBITDA margin
89.5%
+153% vs 2023
Equity ratio
78.0%
Financial strength
Net profit 2024
SEK 200K
+158% vs 2023
| Revenue | SEK 274K | +172% |
| EBITDA | SEK 245K | +153% |
| Net profit | SEK 200K | +158% |
| Total assets | SEK 411K | +164% |
| Equity | SEK 320K | +166% |
| Employees | 1 | — |
Legal name
Specio AB
Org number
5591087662
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
12 april 2017
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget ska erbjuda tekniska och medicinska konsulttjänster samt därmed förenlig verksamhet.
Address
Lägergränden 15
Email
speciolabs@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 101 | 274 |
| Staff expenses | — | — | — | −1 | −0 |
| EBITDA | −1 | −1 | −1 | 97 | 245 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | −1 | −1 | −1 | 97 | 245 |
| Net financials | — | — | — | — | 7 |
| Profit before tax | −1 | −1 | −1 | 97 | 251 |
| Tax | −0 | −0 | −0 | −19 | −52 |
| Net profit | −1 | −1 | −1 | 77 | 200 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 46 | 45 | 43 | 155 | 411 |
| Equity | 46 | 45 | 43 | 121 | 320 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 0 | 0 | 0 | 35 | 90 |
| Total debt | — | — | — | 35 | 90 |
EBITDA margin
89.5%
This company
15.8%
Market median
+466% vs market
20202024
Equity ratio
78.0%
This company
38.2%
Market median
+104% vs market
20202024
Return on equity
62.3%
This company
18.4%
Market median
+239% vs market
20202024
Net profit margin
72.9%
This company
8.1%
Market median
+800% vs market
20202024
Asset turnover
0.67×
This company
1.12×
Market median
-40% vs market
20202024
Debt / equity
0.28×
This company
0.62×
Market median
+55% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Specio AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kristin Sofie Elisabet Johnson | Board of Directors | 0 companies |
| Carl Magnus Theo Johnson | Deputy Board Member | 0 companies |